Allen Institute · 15 hours ago
Summer Intern – Immunology: Human Antigen-Specific T Cell AIM Assay Development
The Allen Institute is dedicated to understanding the principles that govern life and advancing health through innovative research. They are seeking a summer intern to contribute to the development of a human antigen-specific T cell Activation-Induced Marker assay, focusing on flow cytometry and cellular immunology techniques.
Neuroscience
Responsibilities
Learn how to safely handle and culture human blood cells (PBMC) in a BSL2 laboratory; complete Allen Institute Biosafety and general laboratory practice training module
Cellular immunology techniques: Thaw, count, culture, and activate primary human PBMCs
Flow cytometry: Learn how to operate a Beckman CytoFlex LX spectral flow cytometer, analyze and process data through FlowJo or CellEngine software
MSD multiplex cytokine assays: Learn how to set up and analyze quantitative multiplex cytokine assays using MSD, ECL technology platform
Assay design and protocol optimization: Adjust conditions for cell resting and stimulation to ensure robust, reproducible results
Scientific research methods: Engage with literature and established methods to inform project design and execution
Qualification
Required
Must be enrolled in, or a 2026 graduate of an accredited associate's, bachelor's, or master's degree program
Must be able to start on June 1st, June 15th, or June 29th, 2026 and commit to the full 10-week program
Must be eligible to work in the United States for the duration of the internship
Must be 18 years of age or older
Interest in, and basic understanding of immunology
Basic Microsoft computer skills including Word, Excel, and PowerPoint
Benefits
Interns will accrue paid sick days
Receive a free Seattle transportation card (ORCA Business Passport)
Travel and/or housing stipend available to qualifying interns
Company
Allen Institute
The Allen Institute is dedicated to answering some of the biggest questions in bioscience and accelerating research worldwide.
Funding
Current Stage
Late StageRecent News
2025-12-25
2025-12-24
Company data provided by crunchbase